Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07284654 · ClinicalTrials.gov registry record · Phase 3

Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Immunobridging to Adults 18-49

A Phase 3 study of Pneumococcal Vaccines, sponsored by Vaxcyte.

Recruiting
Registry status
Phase 3
Development phase
4,000
Enrollment target
20
Study locations

NCT07284654 is a Phase 3 study of Pneumococcal Vaccines that is actively recruiting participants, run by Vaxcyte. The registered enrollment target is 4,000 participants, above the 787-participant average among 5 other Pneumococcal Vaccines trials with a reported enrollment target (408% higher). The trial reports 20 study locations across 14 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07284654, a Phase 3 study of Pneumococcal Vaccines, is actively recruiting participants, sponsored by Vaxcyte.

RECRUITING
Registry status
Phase 3
Development phase
4,000 participants
Enrollment target
20
Study locations

Study Summary

The primary objectives of this study are to evaluate the safety, tolerability, immunologic noninferiority (for shared serotypes) and immunologic superiority (for novel serotypes) of VAX-31 compared to PCV21 and PCV20 in adults ≥50 years of age, and to bridge the immune responses induced by VAX-31 in adults 50-64 years of age to adults 18-49 years of age.

Conditions Studied

Pneumococcal Vaccines

Interventions

  • BIOLOGICAL PCV21
  • BIOLOGICAL 31 valent pneumococcal conjugate vaccine
  • BIOLOGICAL PCV20

Study Locations (20)

Florida

  • Research Centers of America - Hollywood - CenExel - Hollywood
  • Health Awareness - Jupiter - ERN - Jupiter
  • Suncoast Research Group LLC - Miami
  • Precision Clinical Research - Sunrise - Sunrise

Arizona

  • Center for Indigenous Health - Chinle - Johns Hopkins Project - Chinle
  • Center for Indigineous Health - Whiteriver - John Hopkins Project - Whiteriver

Kansas

  • Johnson County Clin-Trials - JCCT - Lenexa
  • Alliance for Multispecialty Research, LLC - West Wichita - Wichita

Mississippi

  • DelRicht Research, LLC - Gulfport - Gulfport
  • Sky Integrative Medical Center - SKYCRNG - Ridgeland

Alabama

  • Accel Research Site - Achieve - Birmingham - ERN - Birmingham

California

  • Clinical Innovations Trials - Riverside - CenExel - Riverside

Georgia

  • Clinical Research Atlanta - Headlands - Stockbridge

Indiana

  • Velocity Clinical Research - Valparaiso (Buynak Clinical Research) - Valparaiso

Trial Details

FieldValue
Enrollment Target 4,000 participants
Start Date 2025-12-01
Est. Completion 2027-01
Phase Phase 3

Sponsor

Vaxcyte

8 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07284654

The ClinicalTrials.gov registry entry for NCT07284654 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 4,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 787-participant average among 5 other Pneumococcal Vaccines trials with a reported enrollment target (408% higher). The listed sponsor is Vaxcyte, which has 8 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Pneumococcal Vaccines appearing as the primary indexed condition, and to 3 interventions - of which PCV21 is the first listed.

NCT07284654 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Florida, Arizona, Kansas.

Frequently Asked Questions

What is clinical trial NCT07284654 about?

NCT07284654 is a clinical study titled "Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Immunobridging to Adults 18-49". The primary objectives of this study are to evaluate the safety, tolerability, immunologic noninferiority (for shared serotypes) and immunologic superiority (for novel serotypes) of VAX-31 compared to PCV21 and PCV20 in adults ≥50 years of age, and to bridge the immune responses induced by VAX-31 in...

What is the current status of trial NCT07284654?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 4,000 participants. The study started on 2025-12-01. Estimated completion is 2027-01.

What conditions does trial NCT07284654 study?

This clinical trial studies the following conditions: Pneumococcal Vaccines.

What interventions are being tested in trial NCT07284654?

The interventions under investigation include: PCV21 (BIOLOGICAL), 31 valent pneumococcal conjugate vaccine (BIOLOGICAL), PCV20 (BIOLOGICAL).

Who is sponsoring clinical trial NCT07284654?

This trial is sponsored by Vaxcyte, which has 8 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07284654 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Pneumococcal Vaccines

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Pneumococcal Vaccines

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.